FDA has approved new indications for Simparica Trio® (sarolaner, moxidectin and pyrantel chewable tablets), Simparica® (sarolaner) Chewables, and Revolution® Plus (selamectin and sarolaner topical solution). Simparica received approval for the treatment and control of infestations with Haemaphysalis longicornis (Asian longhorned tick) in dogs 6 months of age and older weighing 2.8 pounds and greater. The FDA also approved a new label indication for Revolution Plus for the prevention of Dipylidium caninum (tapeworm) infections at the source.
Source: Zoetis, January 14, 2025. Link.
Leave a Reply